Are Parkinson's Disease Patients the Ideal Preclinical Population for Alzheimer's Disease Therapeutics?

被引:2
|
作者
Tropea, Thomas F. [1 ]
Chen-Plotkin, Alice [1 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA
来源
JOURNAL OF PERSONALIZED MEDICINE | 2021年 / 11卷 / 09期
关键词
Parkinson's disease; Alzheimer's disease; clinical trial; precision medicine; CEREBROSPINAL-FLUID BIOMARKERS; COGNITIVE IMPAIRMENT; NATIONAL INSTITUTE; ALPHA-SYNUCLEIN; DEMENTIA; TAU; CSF; ASSOCIATION; NEUROPATHOLOGY; EPIDEMIOLOGY;
D O I
10.3390/jpm11090834
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Concomitant neuropathological hallmarks of Alzheimer's Disease (AD) are common in the brains of people with Parkinson's disease (PD). Furthermore, AD biomarkers are associated with cognitive decline and dementia in PD patients during life. Here, we highlight the considerable overlap between AD and PD, emphasizing neuropathological, biomarker, and mechanistic studies. We suggest that precision medicine approaches may successfully identify PD patients most likely to develop concomitant AD. The ability to identify PD patients at high risk for future concomitant AD in turn provides an ideal cohort for trials of AD-directed therapies in PD patients, aimed at delaying or preventing cognitive symptoms.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Splicing therapeutics for Alzheimer's disease
    Wasser, Catherine R.
    Herz, Joachim
    EMBO MOLECULAR MEDICINE, 2016, 8 (04) : 308 - 310
  • [32] Frontiers in Alzheimer's disease therapeutics
    Stone, Jeremy G.
    Casadesus, Gemma
    Gustaw-Rothenberg, Kasia
    Siedlak, Sandra L.
    Wang, Xinglong
    Zhu, Xiongwei
    Perry, George
    Castellani, Rudy J.
    Smith, Mark A.
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2011, 2 (01) : 9 - 23
  • [33] Update on Alzheimer's Disease Therapeutics
    Rafii, Michael S.
    REVIEWS ON RECENT CLINICAL TRIALS, 2013, 8 (02) : 110 - 118
  • [34] Therapeutics options of Alzheimer's disease
    Carpio, A
    REVISTA ECUATORIANA DE NEUROLOGIA, 2000, 9 (03): : 36 - 43
  • [35] Therapeutics of Neurotransmitters in Alzheimer's Disease
    Kandimalla, Ramesh
    Reddy, P. Hemachandra
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 57 (04) : 1049 - 1069
  • [36] Emerging Therapeutics for Alzheimer's Disease
    Chiang, Karen
    Koo, Edward H.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54, 2014, 54 : 381 - 405
  • [37] Novel therapeutics for Alzheimer’s disease
    Rudolph E. Tanzi
    Neurotherapeutics, 2008, 5 : 377 - 380
  • [38] Emerging therapeutics for Alzheimer's disease
    Vardy, Emma R. L. C.
    Hussain, Ishrut
    Hooper, Nigel M.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2006, 6 (05) : 695 - 704
  • [39] Preclinical (premotor) Parkinson’s disease
    E. Ch. Wolters
    C. Francot
    P. Bergmans
    A. Winogrodzka
    J. Booij
    H. W. Berendse
    J. C. Stoof
    Journal of Neurology, 2000, 247 (Suppl 2) : 103 - 109
  • [40] Preclinical diagnosis of Parkinson's disease
    Oertel, W. H.
    Eggert, K. M.
    Moeller, C. J.
    Mayer, T. J. J. Geert
    Behlke, M.
    Knake, S.
    Unger, M. M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 7 - 7